{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/menopause/management/management-of-menopause-perimenopause-or-premature-ovarian-insufficiency/","result":{"pageContext":{"chapter":{"id":"9c13d541-f2ee-5d0a-a174-cd7c7b4aa392","slug":"management-of-menopause-perimenopause-or-premature-ovarian-insufficiency","fullItemName":"Scenario: Management of menopause, perimenopause, or premature ovarian insufficiency","depth":2,"htmlHeader":"<!-- begin field 19cfcc44-11bc-4ea5-b311-6f2a991d2d0b --><h2>Scenario: Managing women with menopause, perimenopause, or premature ovarian insufficiency</h2><!-- end field 19cfcc44-11bc-4ea5-b311-6f2a991d2d0b -->","summary":"Covers the management of women with menopause, perimenopause, or premature ovarian insufficiency, including lifestyle strategies, non-drug treatments, and/or drug treatment options, and when to refer.","htmlStringContent":"<!-- begin item 480185a2-9912-4856-9b79-b16c686d702d --><!-- begin field 921d632d-c750-4f7e-8fbc-acbd00859b4c --><p>From age 35 years onwards (Female).</p><!-- end field 921d632d-c750-4f7e-8fbc-acbd00859b4c --><!-- end item 480185a2-9912-4856-9b79-b16c686d702d -->","topic":{"id":"69003588-b736-585d-8a5d-7ca0e916caa5","topicId":"f75fa6a7-10c6-4887-9cf1-3ea14d7f353c","topicName":"Menopause","slug":"menopause","lastRevised":"Last revised in November 2020","chapters":[{"id":"0359e5fa-1342-5767-a4da-2f8b5cd2b6db","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"c978ff88-dda8-5879-a0ac-9b09182d81d1","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"d381eed9-6611-5263-a3be-b46ec9f02058","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"ddcba55c-566e-5433-8dce-2e5f5cee0ba4","slug":"changes","fullItemName":"Changes"},{"id":"e521b2f5-34d4-580f-b63d-a1ec2d0c13a3","slug":"update","fullItemName":"Update"}]},{"id":"ab5690cf-81b4-5fa9-b69f-27abc2e034a3","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c0f45ff8-442c-5027-922e-12d108200960","slug":"goals","fullItemName":"Goals"},{"id":"8459ae09-bdf2-5d0d-9728-538e93d05a8f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"43027e52-84ef-53fa-88c5-a84289154e48","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4620ee3c-97ae-5f9f-8bac-fc8497801cdb","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"b26fb3cf-562a-595a-8f9e-92fd752d2e6b","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"10c1cb80-22cc-5889-8e30-35cf1a9843bf","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"18c173af-ec8a-571c-be49-d894f0bec50b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8e86f5f5-2343-5ea3-8d0d-7dda791a066e","slug":"definition","fullItemName":"Definition"},{"id":"17295b39-3f33-5e75-8d8a-1fc32c2efb70","slug":"causes","fullItemName":"Causes"},{"id":"5b768dab-f7db-50c3-8686-0d363f36e74d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"698848d3-f122-5e5a-acc8-98518854f51b","slug":"complications","fullItemName":"Complications"},{"id":"647a928d-775d-5b0b-b577-b695140b26a3","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"00aeafb7-f9e4-5fd2-8fd2-57bd7fd333d8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d68ce2dd-2971-5c66-b22c-df0db848cf06","slug":"diagnosis-of-menopause-perimenopause","fullItemName":"Diagnosis of menopause and perimenopause"},{"id":"8b9c8208-91c2-5751-8a76-dc9461736050","slug":"diagnosis-of-premature-ovarian-insufficiency","fullItemName":"Diagnosis of premature ovarian insufficiency"},{"id":"a84016e1-b7af-55f9-b1f8-c85ff76cfc93","slug":"assessment","fullItemName":"Assessment"},{"id":"6c51a87c-f89c-5e58-b495-39506bc70e62","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"649507f8-7b95-5740-9833-fee7c5bff092","fullItemName":"Management","slug":"management","subChapters":[{"id":"9c13d541-f2ee-5d0a-a174-cd7c7b4aa392","slug":"management-of-menopause-perimenopause-or-premature-ovarian-insufficiency","fullItemName":"Scenario: Management of menopause, perimenopause, or premature ovarian insufficiency"}]},{"id":"7d937659-3134-52f9-8742-b90a6ffb1f1f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"19b6008a-dd02-5fdb-b146-5cb427bb1f29","slug":"hormone-replacement-therapy-hrt","fullItemName":"Hormone replacement therapy (HRT)"}]},{"id":"ff6b5c36-2033-50a7-9c74-c9e46f1c8242","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"c9280136-8c1b-5890-96e2-c8f14078bb5f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"4f9c2c0d-8ea0-5048-8ae4-0b2517bed5ca","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4b187b70-dcd7-5e05-ac85-fd75204e2515","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b3e44a7a-44e1-5dec-bd9e-67a0cad5baca","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"6e1b4175-c43f-53ce-8884-b9f1b5b39f58","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6e0d3a8f-c4c1-533c-b265-34d08681175b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e6340cdd-13d8-5fde-912f-a3d2c50f305f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"649507f8-7b95-5740-9833-fee7c5bff092","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"c98d0631-b232-5423-93c3-2a91dfc480cb","slug":"information-lifestyle-advice","fullItemName":"Information and lifestyle advice","depth":3,"htmlHeader":"<!-- begin field 38b75c1b-2462-4875-b74a-065563081576 --><h3>What information and advice should I give a woman diagnosed with menopause?</h3><!-- end field 38b75c1b-2462-4875-b74a-065563081576 -->","summary":null,"htmlStringContent":"<!-- begin item c8d569c7-aa59-438b-9c22-e9db2171b64d --><!-- begin field 158804b7-58f7-4040-95ba-c94db5e6e8e3 --><ul><li><strong>Provide evidence-based information about menopause and treatment options to help women make informed, individualized decisions about management,</strong> including:<ul><li>The stages of menopause, common symptoms, and short- and long-term health implications.</li><li>Treatment options, such as lifestyle measures, <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/management/management-of-menopause-perimenopause-or-premature-ovarian-insufficiency/#non-hormonal-treatments\">non-hormonal treatments</a>, and <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/management/management-of-menopause-perimenopause-or-premature-ovarian-insufficiency/#hormone-replacement-therapy-hrt\">hormonal drug treatments</a>.</li><li>Information and advice about support organizations, such as:<ul><li>Rock My Menopause website (<a href=\"https://rockmymenopause.com/\" data-hyperlink-id=\"8956696e-c1e2-4c9f-a675-ac75010b0347\">www.rockmymenopause.com</a>) has a variety of factsheets and podcasts on various aspects of menopause.</li><li>Menopause Matters (<a href=\"https://www.menopausematters.co.uk/\" data-hyperlink-id=\"e947e9c6-8d79-42b1-8cdc-ac75010b071e\">www.menopausematters.co.uk</a>) provides information on the menopause, menopausal symptoms, and treatment options.</li><li>Women's Health Concern (the patient arm of the British Menopause Society, website available at <a href=\"https://www.womens-health-concern.org/\" data-hyperlink-id=\"31d217aa-8189-42c1-a83b-ac75010b0762\">www.womens-health-concern.org</a>) has a range of factsheets and an email advice service.</li><li>The Royal College of Obstetricians and Gynaecologists (<a href=\"https://www.rcog.org.uk/en/\" data-hyperlink-id=\"fbe13664-7763-4f18-b387-ac75010b0795\">www.rcog.org.uk</a>) has various patient leaflets in the section on <a href=\"https://www.rcog.org.uk/en/patients/menopause/\" data-hyperlink-id=\"44e860ee-86dd-45b8-b61f-ac75010b0865\">Menopause and women's health in later life</a>.</li><li>The Daisy Network (<a href=\"https://www.daisynetwork.org/\" data-hyperlink-id=\"440d5a94-87db-4266-9d6b-ac75010b0880\">www.daisynetwork.org</a>) is a nationwide support group for women diagnosed with premature ovarian insufficiency or premature menopause.</li><li>The NHS leaflet <a href=\"https://www.nhs.uk/conditions/menopause/\" data-hyperlink-id=\"a1965bed-1b5c-4031-b13a-ac75010b0892\">Menopause</a>.</li></ul></li></ul></li><li><strong><strong><strong>Give information and advice on lifestyle measures for menopause symptom relief.</strong></strong></strong><ul style=\"font-weight: 400;\"><li>Hot flushes and night sweats — regular exercise, weight loss (if applicable), wearing lighter clothing/layers of clothing, turning down central heating, sleeping in a cooler room, using fans, reducing stress, and avoiding possible triggers (such as spicy foods, caffeine, smoking, and alcohol). See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a>, <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/alcohol-problem-drinking/\">Alcohol - problem drinking</a> for more information.</li><li>Sleep disturbances — avoiding exercise late in the day and maintaining a regular bedtime. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/insomnia/\">Insomnia</a> for more information.</li><li>Low mood and anxiety — adequate sleep, regular physical activity, and relaxation exercises.</li><li>Cognitive symptoms — exercise and good sleep hygiene.</li></ul></li><li><strong>Give information and advice on general health measures that may improve quality of life.</strong><ul><li>Advise the woman to seek occupational health advice if support is needed in the workplace.</li><li>Advise on measures to manage cardiovascular risk factors if a women has, or is at increased risk of, cardiovascular disease. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a> for more information.</li><li>Encourage engagement with national screening programmes (if appropriate). See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/cervical-screening/\">Cervical screening</a>, <a class=\"topic-reference external-reference\" href=\"/topics/breast-screening/\">Breast screening</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/bowel-screening/\">Bowel screening</a> for more information.</li><li>Advise on bone health, especially if a woman is diagnosed with premature menopause or <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/diagnosis/diagnosis-of-premature-ovarian-insufficiency/\">primary ovarian insufficiency</a>. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/\">Osteoporosis - prevention of fragility fractures</a> for more information.</li><li>Advise on the need for contraception. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/\">Contraception - assessment</a> for more information.<ul><li>Advise that hormone replacement therapy (HRT) does not provide contraception.</li><li>Advise that a woman is potentially fertile for 2 years after her last menstrual period if she is younger than 50 years of age, and for 1 year if she is over 50 years of age.</li><li>Advise that in general all women can stop contraception at the age of 55 years.</li><li>Be aware that all progestogen-only methods of contraception are safe to use alongside <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/prescribing-information/hormone-replacement-therapy-hrt/#regimen\">cyclical HRT</a>. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a> for more information.</li><li>Be aware that combined hormonal contraception can be used in eligible women under 50 years of age as an alternative to HRT for relief of menopausal symptoms and prevention of loss of bone mineral density. Women should be advised to switch to a progestogen-only method of contraception at 50 years of age, if needed. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a> for more information.</li></ul></li></ul></li></ul><!-- end field 158804b7-58f7-4040-95ba-c94db5e6e8e3 --><!-- end item c8d569c7-aa59-438b-9c22-e9db2171b64d -->","subChapters":[{"id":"50edc9b0-26fe-568d-bacd-e1e7c91e589e","slug":"basis-for-recommendation-d7f","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 6fc19c3f-ed68-4a7b-8dae-ca1e33dcc991 --><h4>Basis for recommendation</h4><!-- end field 6fc19c3f-ed68-4a7b-8dae-ca1e33dcc991 -->","summary":null,"htmlStringContent":"<!-- begin item d7fbbed6-9391-49ad-b251-c3a11c48d4d0 --><!-- begin field 5f3e0ded-e5ec-4029-b52a-b6093f24ce30 --><p>The recommendations on information and lifestyle advice are based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Menopause</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>]; the European Menopause and Andropause Society (EMAS) position statements <em>Non-hormonal management of menopausal vasomotor symptoms</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Mintziori, 2015</a>], <em>Maintaining postreproductive health: a care pathway from the European Menopause and Andropause Society (EMAS)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Armeni, 2016</a>], and <em>EMAS recommendations for conditions in the workplace for menopausal women</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Griffiths, 2016</a>]; the British Menopause Society (BMS) publication <em>Consensus on the management of estrogen deficiency symptoms, arthralgia, and menopause diagnosis in women treated for early breast cancer</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Marsden, 2019</a>]; the Endocrine Society clinical practice guideline <em>Treatment of symptoms of the menopause</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Stuenkel, 2015</a>]; the American Association of Clinical Endocrinologists (AACE) consensus publication <em>Medical guidelines for clinical practice for the diagnosis and treatment of menopause</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Goodman, 2011</a>]; the North American Menopause Society position statement <em>Nonhormonal management of menopause-associated vasomotor symptoms</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">North American Menopause Society, 2015</a>]; the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline <em>Contraception for women aged over 40 years</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">FSRH, 2019</a>]; and expert opinion in review articles on hormonal treatments [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hill, 2016</a>], on non-hormonal therapies [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hickey, 2017</a>], and in a medical textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Rees, 2009</a>].</p><h6>Providing information and advice on menopause and treatment options</h6><ul><li>The recommendation to provide information on menopause and treatment options to allow an individualized approach to management is based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>] and the EMAS position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Armeni, 2016</a>].<ul><li>NICE reviewed the evidence from 28 studies of very low- to moderate-quality, to establish the most common areas of information needs for women in the menopause, and the most effective ways of delivering this information.<ul><li>General information on the menopause, the risks and benefits of hormone replacement therapy (HRT) and non-hormonal treatments for menopause were widely reported as a common theme of information needs for women in the menopause. Fertility, sexuality, and finding sources of emotional support were also identified.</li><li>Different areas of information provision are important for women in the menopause, including information on menopause symptoms and the different treatment options.</li><li>There may be specific information needs for women with premature menopause (such as information on fertility).</li></ul></li></ul></li></ul><h6>Providing information and advice on lifestyle measures</h6><ul><li>The recommendations on lifestyle measures for menopausal symptoms are based on limited and conflicting evidence in the literature in the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>], the EMAS position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Mintziori, 2015</a>], the AACE consensus publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Goodman, 2011</a>], North American Menopause Society position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">North American Menopause Society, 2015</a>], the Endocrine Society clinical practice guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Stuenkel, 2015</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hill, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hickey, 2017</a>] and in a medical textbook<em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Rees, 2009</a>].<ul><li>The AACE consensus publication recommends weight loss, regular exercise, stopping smoking, and drinking alcohol within recommended limits, which have the additional benefits of reducing cardiovascular risk. In addition, it recommends the use of fans and light cotton clothing for the management of vasomotor symptoms.</li><li>The Endocrine Society guideline recommends that all women should be advised about appropriate lifestyle measures for vasomotor symptoms, based on low-quality evidence, and notes that obesity is a risk factor for developing such symptoms.</li><li>The North American Menopause Society position statement states that weight loss and mindfulness-based stress reduction techniques may be beneficial for reducing vasomotor symptoms based on variable-quality evidence, but additional studies are needed. It found negative, insufficient, or inconclusive data suggesting that cooling techniques, avoidance of triggers, exercise, yoga, paced respiration, and relaxation techniques should not be recommended as proven therapies for managing vasomotor symptoms.</li><li>The EMAS position statement on non-hormonal management found insufficient or conflicting evidence on the impact of physical exercise on the frequency and severity of vasomotor symptoms, and inconsistent results for the use of relaxation and yoga for the relief of vasomotor symptoms [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Mintziori, 2015</a>].</li><li>Expert opinion in a review article found no high-quality, consistent evidence that yoga, paced respiration, exercise, stress reduction, or relaxation therapy benefit women more than placebo for the relief of vasomotor symptoms, based on limited evidence [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hill, 2016</a>]. Similarly, expert opinion in an additional review found no evidence to support the use of mindfulness-based stress reduction or relaxation techniques for the management of vasomotor symptoms. It also found no high-quality evidence for cooling down measures such as dressing in layers, and no evidence for paced breathing. It found low-quality evidence that exercise and yoga does not improve vasomotor symptoms or sleep but noted that exercise is likely to provide other health benefits [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hickey, 2017</a>].</li></ul></li></ul><h6>Providing information and advice on general health measures</h6><ul><li>The recommendations on general health measures are based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>], the FSRH clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">FSRH, 2019</a>], the EMAS position statements [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Mintziori, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Armeni, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Griffiths, 2016</a>], the AACE consensus publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Goodman, 2011</a>], and the Endocrine Society clinical practice guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Stuenkel, 2015</a>].<ul><li>The recommendation to seek occupational health advice is based on the EMAS position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Griffiths, 2016</a>]. It is also pragmatic, based on what CKS considers to be good clinical practice.</li><li>The recommendation to manage cardiovascular risk factors is extrapolated from the NICE clinical guideline, which notes that lifestyle changes and interventions can help general health and wellbeing. Similarly, the EMAS position statement notes that exercise may improve quality of life, improve cognitive and physical function, and reduce all-cause mortality [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Mintziori, 2015</a>]. The AACE consensus publication highlights that smoking can increase the risk of cardiovascular disease and venous thromboembolism when taking oestrogen therapy.</li><li>The recommendation to encourage engagement with national screening programmes is based on the NICE clinical guideline, together with the EMAS position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Armeni, 2016</a>], and the Endocrine Society clinical practice guideline.</li><li>The recommendation to advise on bone health is based on the NICE clinical guideline.</li><li>The recommendation to advise about contraception is based on the NICE clinical guideline, the FSRH clinical guideline, and the EMAS position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Armeni, 2016</a>].<ul><li>The information that HRT is not a contraceptive is based on the NICE clinical guideline.</li><li>The information on when contraception may be stopped is based on the FSRH clinical guideline.</li><li>The information that most women can stop contraception at the age of 55 years is based on the FSRH clinical guideline, which states that spontaneous conception after this age is exceptionally rare, even in women still experiencing menstrual bleeding, and natural loss of fertility can be assumed for most women.</li><li>The information that progestogen-only methods can be used alongside cyclical HRT is based on the FSRH clinical guideline.</li><li>The information that combined hormonal contraception can be used as an alternative to HRT in eligible women is based on the FSRH clinical guideline.</li></ul></li></ul></li></ul><!-- end field 5f3e0ded-e5ec-4029-b52a-b6093f24ce30 --><!-- end item d7fbbed6-9391-49ad-b251-c3a11c48d4d0 -->","subChapters":[]}]},{"id":"e21a4607-3f99-5bd0-9808-e1defc0528a4","slug":"hormone-replacement-therapy-hrt","fullItemName":"Hormone replacement therapy (HRT)","depth":3,"htmlHeader":"<!-- begin field 57e2c4d7-d35c-451d-801a-42e15a9ec57a --><h3>How should I manage menopausal symptoms with hormone replacement therapy?</h3><!-- end field 57e2c4d7-d35c-451d-801a-42e15a9ec57a -->","summary":null,"htmlStringContent":"<!-- begin item 054779e9-a367-4f78-ab08-744534dec11a --><!-- begin field cfa64d7a-2b42-49e7-9a11-5109eb9aa1d1 --><p><strong>If a woman wishes to consider the use of hormone replacement therapy (HRT) for management of menopausal symptoms:</strong></p><ul><li><strong>Advise on lifestyle measures for menopause symptom relief.</strong> See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/management/management-of-menopause-perimenopause-or-premature-ovarian-insufficiency/#information-lifestyle-advice\">Information and lifestyle advice</a> for more information.</li><li><strong>Offer an individualized choice of HRT preparation, based on her age, symptoms, and <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/management/management-of-menopause-perimenopause-or-premature-ovarian-insufficiency/#managing-co-morbidities\">co-morbidities</a>, after discussing potential<strong> <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/management/management-of-menopause-perimenopause-or-premature-ovarian-insufficiency/#risks-of-hrt\">risks</a>,<strong><strong> <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/management/management-of-menopause-perimenopause-or-premature-ovarian-insufficiency/#benefits-of-hrt\">benefits</a>,</strong></strong> <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/prescribing-information/hormone-replacement-therapy-hrt/#adverse-effects\">adverse effects</a>, and <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/prescribing-information/hormone-replacement-therapy-hrt/#contraindications-cautions\">contraindications</a></strong><strong>. Aim to prescribe</strong> the lowest dose for the shortest possible duration.</strong><ul><li><strong>For vasomotor symptoms:</strong><ul><li>In women with a uterus, offer an oral or transdermal combined (oestradiol plus progestogen) preparation.</li><li>In women without a uterus, offer an oral or transdermal oestrogen-only preparation.</li><li>In eligible women under 50 years of age, offer a choice of HRT or a combined hormonal contraceptive as an alternative option, if there are no contraindications. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/\">Contraception - assessment</a> for more information.</li></ul></li><li><strong>For mood disorders, </strong>offer a choice of oral or transdermal HRT preparations.</li><li><strong>For urogenital symptoms (genitourinary syndrome of menopause):</strong><ul><li>Offer low-dose vaginal oestrogen first-line and continue treatment for as long as needed to relieve symptoms. Note: some women on systemic HRT may also benefit from additional low-dose vaginal oestrogen.</li><li>If a low-dose preparation does not relieve symptoms sufficiently, consider seeking specialist advice about increasing the dose.</li><li>If low-dose vaginal oestrogen is not tolerated or is contraindicated, consider a trial of oral ospemifene (a selective oestrogen receptor modulator) if there are moderate-to-severe symptoms and no contraindications, depending on local prescribing guidelines. </li><li>Advise that <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/management/management-of-menopause-perimenopause-or-premature-ovarian-insufficiency/#non-hormonal-treatments\">vaginal moisturizers and lubricants</a> can be used alone or in addition to vaginal oestrogen preparations.</li></ul></li><li><strong>For altered sexual function, </strong>seek specialist advice on the appropriateness of testosterone supplementation (off-label indication). See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/management/management-of-menopause-perimenopause-or-premature-ovarian-insufficiency/#referral\">Referral</a> for more information.</li><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/prescribing-information/hormone-replacement-therapy-hrt/\">Prescribing information</a> for detailed information on <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/prescribing-information/hormone-replacement-therapy-hrt/#route-of-administration\">choosing a route of administration</a>, <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/prescribing-information/hormone-replacement-therapy-hrt/#choice-of-hormone\">choice of hormone</a>, and <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/prescribing-information/hormone-replacement-therapy-hrt/#regimen\">recommended regimes</a>.<ul><li>Be aware that women with premature menopause or <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/background-information/definition/\">premature ovarian insufficiency</a> (POI) may need high oestrogen doses for symptom relief, whereas older women may need to start or be maintained on a lower oestrogen dose.</li><li>If there is any uncertainty about the safety or appropriateness of prescribing HRT, liaise with the woman's relevant specialist, or seek advice from a health professional with expertise in menopause.</li></ul></li></ul></li><li><strong>Do not recommend the use of bioidentical hormone replacement therapy.</strong></li><li><strong>Arrange to review the woman after 3 months if HRT has been started or changed, then at least annually thereafter,</strong> unless there are clinical indications for an earlier review (such as treatment ineffectiveness or adverse effects). At each review:<ul><li>Reinforce <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/management/management-of-menopause-perimenopause-or-premature-ovarian-insufficiency/#information-lifestyle-advice\">information and lifestyle advice</a>.</li><li>Assess the efficacy and tolerability of treatment(s).</li><li>Assess for bothersome <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/prescribing-information/hormone-replacement-therapy-hrt/#adverse-effects\">adverse effects</a> or persistent symptoms, and offer to adjust the HRT dose or preparation if appropriate. Options include:<ul><li>Reduce the dose of oestrogen.</li><li>Change the dose or type of progestogen.</li><li>Alter the route of administration, for example switch from oral to transdermal.</li><li>Switch to a combined oestrogen/bazedoxifene acetate preparation (a selective oestrogen receptor modulator), if progestogen-containing therapy is not appropriate. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/prescribing-information/hormone-replacement-therapy-hrt/#choice-of-hormone\">Choice of hormone</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/prescribing-information/\">Prescribing information</a> for more information.</li></ul></li><li>If there is a sudden change in menstrual pattern, intermenstrual bleeding, postcoital bleeding, or postmenopausal bleeding — assess appropriately and arrange an urgent 2-week referral if a gynaecological cancer is suspected. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/gynaecological-cancers-recognition-referral/\">Gynaecological cancers - recognition and referral</a> for more information.</li><li>If there are persistent symptoms despite adjustment of the HRT dose or preparation, consider an <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/diagnosis/differential-diagnosis/\">alternative cause</a> for symptoms.</li><li>Review the duration of HRT treatment.<ul><li>If HRT was started in the perimenopause, discuss the option of changing the treatment <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/prescribing-information/hormone-replacement-therapy-hrt/#regimen\">regimen</a> and/or reducing the dose of oestrogen.</li></ul></li></ul></li><li><strong>Support the woman to make an individual decision on when and how to stop HRT. Advise that:</strong><ul><li>HRT should be continued for as long as benefits of symptom control and improved quality of life outweigh any risks, and there is no arbitrary limit for duration of HRT use.<ul><li>For vasomotor symptoms, most women require 2–5 years of treatment, but some women may need longer.</li><li>Women with premature menopause or POI should take HRT up to the average age of the natural menopause (51 years in the UK), after which the need for ongoing HRT should be reassessed.</li></ul></li><li>HRT may be gradually reduced over 3–6 months, or stopped suddenly, depending on the woman's preferences.<ul><li>Symptoms may recur in the short term after stopping treatment, particularly if HRT is stopped suddenly.</li><li>If troublesome symptoms recur, options include restarting HRT at a low dose, or considering alternative <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/management/management-of-menopause-perimenopause-or-premature-ovarian-insufficiency/#non-hormonal-treatments\">non-hormonal treatments</a>.</li></ul></li><li>Vaginal oestrogen preparations may be required long term, but regular attempts to stop treatment, such as annually, can be made.</li></ul></li></ul><!-- end field cfa64d7a-2b42-49e7-9a11-5109eb9aa1d1 --><!-- end item 054779e9-a367-4f78-ab08-744534dec11a -->","subChapters":[{"id":"e8c61a70-49f7-5e86-a4ca-34443b8a7d40","slug":"risks-of-hrt","fullItemName":"Risks of HRT","depth":4,"htmlHeader":"<!-- begin field a77097a8-3ec0-4801-a7c4-115581a85a0e --><h4>Risks of hormone replacement treatment</h4><!-- end field a77097a8-3ec0-4801-a7c4-115581a85a0e -->","summary":null,"htmlStringContent":"<!-- begin item a514cc2b-3e48-43d3-96a0-e1881d165be2 --><!-- begin field 0ade631d-9337-4d92-9545-fb8e79f70a21 --><ul><li><strong>The National Institute for Health and Care Excellence (NICE) reviewed evidence from mainly randomized controlled trials (RCTs) and comparative cohort studies of very low to moderate quality, on the risks associated with hormone replacement therapy (HRT) <strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>]</strong></strong><strong>:</strong><br><ul><li><strong>Venous thromboembolism (VTE)</strong><ul><li>The risk of VTE associated with HRT is greater for oral than transdermal preparations.</li><li>The risk associated with transdermal HRT given at standard therapeutic doses is no greater than baseline risk.</li></ul></li></ul><ul><li><strong>Coronary heart disease (CHD) and stroke</strong><ul><li>The baseline risk of CHD and stroke for women around menopausal age varies from one woman to another, depending on the presence of cardiovascular risk factors.</li><li>HRT with oestrogen alone is associated with no, or reduced, risk of CHD. Combined HRT with oestrogen and progestogen is associated with little or no increase in the risk of CHD.</li><li>The baseline risk of stroke in women younger than 60 years is very low.</li><li>Oral (but not transdermal) oestrogen is associated with a small increase in the risk of stroke.</li><li>HRT does not increase CVD risk when started in women younger than 60 years.</li><li>HRT does not affect the risk of dying from CVD.</li></ul></li><li><strong>Type 2 diabetes</strong><ul><li>HRT (either orally or transdermally) is not associated with an increased risk of developing type 2 diabetes.</li></ul></li><li><strong>Dementia</strong><ul><li>The likelihood of HRT affecting the risk of dementia is unknown.</li></ul></li><li><strong>Breast cancer</strong><ul><li>The baseline risk of breast cancer for women around menopausal age in the UK varies from one woman to another.</li><li>HRT with oestrogen alone is associated with little or no increase in the risk of breast cancer.</li><li>Combined HRT with oestrogen and progestogen is associated with an increased risk of breast cancer that is dependent on duration of treatment, which reduces after stopping HRT.</li><li>HRT does not affect the risk of dying from breast cancer.</li></ul></li><li><strong>Note: the Medicines and Healthcare products Regulatory Agency (MHRA) drug safety alert on HRT and breast cancer risk cites additional evidence published by the Collaborative Group on Hormonal Factors in Breast Cancer <strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Collaborative Group on Hormonal Factors in Breast Cancer, 2019</a>]</strong> <strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">MHRA, 2019</a>]</strong>:</strong><ul><li>A meta-analysis of 108,647 women with breast cancer in prospective studies has shown that some excess risk of breast cancer with systemic HRT persists for more than 10 years after stopping, compared with never-users.</li><li>There is an increased risk with HRT use duration for longer than 1 year.</li><li>There is an increased risk irrespective of type of oestrogen or progestogen or route of delivery, with slightly lower risks with cyclical compared with continuous combined HRT.</li><li>For women using combined oestrogen-progestogen HRT and oestrogen-only HRT, after stopping HRT the increased risk of breast cancer decreases, and the time needed to return to baseline depends on duration of prior HRT use.</li><li>For women using low-dose vaginal oestrogens, the evidence has not shown an increase in breast cancer in women with no history of breast cancer in the past.</li><li>The MHRA patient leaflet <a href=\"https://assets.publishing.service.gov.uk/media/5d68d0e340f0b607c6dcb697/HRT-patient-sheet-3008.pdf\" data-hyperlink-id=\"6c2d5bf0-da54-4d42-859f-ac7800d9e419\">Hormone replacement therapy and risk of breast cancer</a> may be helpful.</li></ul></li><li><strong>Note: NICE did not discuss ovarian cancer risk in women taking HRT, but the Collaborative Group on Epidemiological Studies of Ovarian Cancer published a meta-analysis of 52 epidemiological studies </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Collaborative Group on Epidemiological Studies of Ovarian Cancer, 2015</a>]<strong>:</strong><ul><li>During prospective follow up, 12,110 postmenopausal women, 55% (6601) of whom had used HRT, developed ovarian cancer.</li><li>Among women last recorded as current users of HRT, the risk was increased even with less than 5 years of use (relative risk [RR] 1.43).</li><li>Combining current or recent use (any duration but stopped less than 5 years before diagnosis) resulted in a RR of 1.37. This risk was similar for oestrogen-only and combined oestrogen-progestogen HRT and was increased for the two most common types of ovarian cancer (serous and endometrioid). The risk declined the longer ago use had stopped, although about 10 years after stopping long-term HRT there was still an excess of serous or endometrioid tumours (RR 1.25).</li><li>The authors of the meta-analysis concluded that 'the increased risk may well be largely or wholly causal; if it is, women who use hormone therapy for 5 years from around age 50 years have about one extra ovarian cancer per 1000 users and, if its prognosis is typical, about one extra ovarian cancer death per 1700 users'.</li></ul></li></ul></li><li>The MHRA (2019) <a href=\"https://assets.publishing.service.gov.uk/media/5d680409e5274a1711fbe65a/Table1.pdf\" data-hyperlink-id=\"dbe0e2f4-c80a-421c-a108-ac7800d9e42b\">Table 1 Summary of HRT risks and benefits during current use and current use plus post-treatment per 1000 women with 5 years or 10 years use of HRT</a> may be useful.</li><li>The MHRA (2019) <a href=\"https://assets.publishing.service.gov.uk/media/5d680384ed915d53b8ebdba7/table2.pdf\" data-hyperlink-id=\"35f0d04e-e2ea-4cbe-9f99-ac7800d9e438\">Table 2 Sum</a><a href=\"https://assets.publishing.service.gov.uk/media/5d680384ed915d53b8ebdba7/table2.pdf\" data-hyperlink-id=\"40f4c3be-d33f-437c-b9a6-ac7800d9e470\">mary of relative and absolute risks and benefits during current HRT use per 1000 women with 5 years or 10 years use of HRT</a> may be useful.</li></ul><!-- end field 0ade631d-9337-4d92-9545-fb8e79f70a21 --><!-- end item a514cc2b-3e48-43d3-96a0-e1881d165be2 -->","subChapters":[]},{"id":"6926eed7-4420-540e-9777-5cf72af93a57","slug":"benefits-of-hrt","fullItemName":"Benefits of HRT","depth":4,"htmlHeader":"<!-- begin field 9b475e88-12ea-4363-b72b-31a217ac32d5 --><h4>Benefits of hormone replacement therapy</h4><!-- end field 9b475e88-12ea-4363-b72b-31a217ac32d5 -->","summary":null,"htmlStringContent":"<!-- begin item ca663df5-966d-4066-ac6f-f75f4ace965e --><!-- begin field 6a2ce3c5-6427-4583-9419-0ec63f2e42fb --><ul><li><strong>The National Institute for Health and Care Excellence (NICE) reviewed the evidence on the additional benefits associated with hormone replacement therapy (HRT) <strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>]</strong>:</strong><ul><li><strong>Fragility fractures</strong><ul><li>The baseline risk of fragility fracture for women around menopausal age in the UK is low and varies from one woman to another.</li><li>The risk of fragility fracture is decreased while taking HRT, and this benefit is maintained during treatment but decreases once treatment stops; this benefit may continue for longer in women who take HRT for longer.</li></ul></li><li><strong>Muscle mass and strength</strong><ul><li>There is limited evidence that HRT may improve muscle mass and strength.</li></ul></li></ul></li><li><strong>NICE reviewed the evidence for women diagnosed with premature menopause/<a class=\"topic-reference internal-reference\" href=\"/topics/menopause/background-information/definition/\">premature ovarian insufficiency</a> <strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>]</strong>:</strong><ul><li>Starting hormonal treatment (either with HRT or a combined hormonal contraceptive) and continuing treatment until at least the age of natural menopause (unless contraindicated) reduces the risk of chronic diseases, including cardiovascular disease and osteoporosis.<ul><li>HRT may have a beneficial effect on blood pressure when compared with a combined hormonal contraceptive.</li><li>Both HRT and combined hormonal contraceptives offer bone protection.</li></ul></li></ul></li><li>The MHRA (2019) <a href=\"https://assets.publishing.service.gov.uk/media/5d680409e5274a1711fbe65a/Table1.pdf\" data-hyperlink-id=\"dbe0e2f4-c80a-421c-a108-ac7800d9e42b\">Table 1 Summary of HRT risks and benefits during current use and current use plus post-treatment per 1000 women with 5 years or 10 years use of HRT</a> may be useful.</li><li>The MHRA (2019) <a href=\"https://assets.publishing.service.gov.uk/media/5d680384ed915d53b8ebdba7/table2.pdf\" data-hyperlink-id=\"35f0d04e-e2ea-4cbe-9f99-ac7800d9e438\">Table 2 Sum</a><a href=\"https://assets.publishing.service.gov.uk/media/5d680384ed915d53b8ebdba7/table2.pdf\" data-hyperlink-id=\"40f4c3be-d33f-437c-b9a6-ac7800d9e470\">mary of relative and absolute risks and benefits during current HRT use per 1000 women with 5 years or 10 years use of HRT</a> may be useful.</li></ul><!-- end field 6a2ce3c5-6427-4583-9419-0ec63f2e42fb --><!-- end item ca663df5-966d-4066-ac6f-f75f4ace965e -->","subChapters":[]},{"id":"7e1c054c-e98b-5c12-ab9a-3af62007e62c","slug":"basis-for-recommendation-513","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 8168aacc-ead4-4fea-bdd8-be11fd8158b3 --><h4>Basis for recommendation</h4><!-- end field 8168aacc-ead4-4fea-bdd8-be11fd8158b3 -->","summary":null,"htmlStringContent":"<!-- begin item 513fd924-abb9-448b-83a9-4e0a613cf978 --><!-- begin field e53e6f70-ec60-4050-89ce-cef68d127c96 --><p>The recommendations on hormone replacement therapy (HRT) are based largely on the National Institute for Health and Care Excellence (NICE) clinical guidelines <em>Suspected cancer: recognition and referral</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2017b</a>] and <em>Menopause</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>]; the European Menopause and Andropause Society (EMAS) position statements <em>Maintaining postreproductive health: a care pathway from the European Menopause and Andropause Society (EMAS)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Armeni, 2016</a>] and <em>Predictors of premature and early natural menopause</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Mishra, 2019</a>]; the British Menopause Society (BMS) publications <em>Testosterone replacement in menopause</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Panay, 2019</a>], <em>HRT-guide</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Ayres, 2020</a>], and <em>The risks and benefits of HRT before and after a breast cancer diagnosis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Marsden, 2020</a>]; the European Society of Human Reproduction and Embryology (ESHRE) guideline <em>Management of women with premature ovarian insufficiency</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">ESHRE, 2015</a>]; the Endocrine Society clinical practice guideline <em>Treatment of symptoms of the menopause</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Stuenkel, 2015</a>]; the American Association of Clinical Endocrinologists (AACE) consensus publication <em>Medical guidelines for clinical practice for the diagnosis and treatment of menopause</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Goodman, 2011</a>]; the AACE and American College of Endocrinology (ACE) <em>Position statement on menopause - 2017 update</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Cobin, 2017</a>]; the North American Menopause Society position statement <em>Nonhormonal management of menopause-associated vasomotor symptoms</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">North American Menopause Society, 2015</a>]; the position statement on hormonal therapy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">North American Menopause Society, 2018</a>]; the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline <em>Contraception for women aged over 40 years</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">FSRH, 2019</a>]; and expert opinion in review articles on hormonal treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hill, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Pinkerton, 2020</a>].</p><h6>Offering an individual choice of HRT preparation</h6><ul><li>The recommendations on offering an individual choice of HRT preparation are based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>], the EMAS position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Armeni, 2016</a>], the AACE consensus publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Goodman, 2011</a>], the Endocrine Society clinical practice guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Stuenkel, 2015</a>], the North American Menopause Society position statements [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">North American Menopause Society, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">North American Menopause Society, 2018</a>], and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hill, 2016</a>].<ul><li>The recommendation to discuss short- and long-term benefits and risks of treatment options including HRT is based on the NICE clinical guideline.</li><li>The recommendation to prescribe the lowest dose for the shortest possible duration is based on the AACE consensus publication and the Endocrine Society clinical practice guideline, which recommends using the lowest effective dose with upward titration based on clinical response. This is due to the fact the risk rates for breast cancer and cardiovascular disease increase with age and time since menopause, and ovarian cancer risk may also increase relative to duration of HRT use. This approach is supported by expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hill, 2016</a>].</li><li>CKS notes that the EMAS position statement highlights that HRT has a favourable risk-benefit profile for women under 60 years of age, or within 10 years after menopause, for menopausal symptoms and osteoporosis risk. Similarly, the Endocrine Society clinical practice guideline states that HRT is the most effective treatment for a range of menopausal symptoms, and benefits may exceed risks for the majority of postmenopausal women under 60 years of age, or under 10 years from the onset of menopause. It recommends that treatment should be individualized depending on the woman's clinical presentation, risks and benefit profile, treatment goals, and personal preference, based on an evaluation of low-quality evidence.</li><li>The North American Menopause Society position statement on non-hormonal therapy notes that head-to-head randomized controlled trials (RCTs) are limited comparing non-hormonal and hormonal treatments, with trials including varying types, doses, and routes of administration of non-hormonal treatments [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">North American Menopause Society, 2015</a>]. The position statement on hormonal therapy states the risks of treatment vary depending on the type, dose, duration of use, route of administration, timing of initiation, and whether progestogen is used. It also states that treatment should be individualized depending on treatment goals, age, time since menopause, health risks, and preferences, based on consensus and expert opinion [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">North American Menopause Society, 2018</a>].</li></ul></li></ul><h6>HRT treatment options for different symptoms</h6><ul><li>The recommendations on management of vasomotor symptoms are based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>], the AACE consensus publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Goodman, 2011</a>], the Endocrine Society clinical practice guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Stuenkel, 2015</a>], the North American Menopause Society position statements [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">North American Menopause Society, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">North American Menopause Society, 2018</a>], the FSRH clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">FSRH, 2019</a>], and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hill, 2016</a>].<ul><li>The NICE evidence review of 51 studies found strong evidence that for women with an intact uterus, when compared with placebo, a transdermal oestradiol plus progestogen was the most effective treatment for vasomotor symptom relief, with a significantly lower discontinuation rate compared with all the other available treatments (hormonal, non-hormonal, and non-drug). There was no strong evidence for the efficacy of oral oestrogen plus progestogen treatment, but the guideline development group supported its use in clinical practice based on its expertise and experience, and noted it may be more effective in relieving vasomotor symptoms than placebo.</li><li>The North American Menopause Society position statement on non-hormonal therapy cites limited evidence suggesting that HRT is more effective than non-hormonal therapy in reducing the frequency and severity of hot flushes.</li><li>The North American Menopause Society position statement on hormonal therapy states that HRT is the most effective treatment for vasomotor and genitourinary symptoms, based on 'good and consistent scientific evidence'.</li><li>The recommendation to offer combined oestrogen and progestogen therapy if a woman has an intact uterus is based on the need for endometrial protection with progestogens, due to the increased risk of endometrial hyperplasia and cancer that occurs with unopposed oestrogen. An oestrogen-only preparation is needed if a woman is without a uterus. These recommendations are based on the NICE clinical guideline, the Endocrine Society clinical practice guideline, the North American Menopause Society position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">North American Menopause Society, 2018</a>], and the AACE consensus publication.</li><li>The recommendation to offer combined hormonal contraception as an alternative to HRT in eligible women under 50 years of age is based on the NICE clinical guideline and the FSRH clinical guideline.</li></ul></li><li>The recommendations on management of mood disorders resulting from the menopause are based on very limited evidence in the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>].<ul><li>It found seven moderate- to very-low quality RCTs that reported variable results with oestrogen therapy compared with placebo, ranging from no effect to a significant reduction in low mood at 8- or 12-week follow up.</li><li>In addition, it reported on six RCTs of moderate- to very-low quality that found a significantly greater reduction in low mood with oestrogen combined with progestogen compared with placebo at up to 24-week follow up.</li></ul></li><li>The recommendations on management of urogenital symptoms are based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>], the EMAS position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Armeni, 2016</a>], the Endocrine Society clinical practice guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Stuenkel, 2015</a>], the North American Menopause Society position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">North American Menopause Society, 2018</a>], and the BMS publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Ayres, 2020</a>].<ul><li>NICE reviewed the evidence of 11 studies of moderate- to very-low quality, on the safety and efficacy of vaginal oestrogen therapy, and found that treatment was safe and effective in relieving symptoms in the short and long term. The guideline development group considered it would be safe to increase the dose of vaginal oestrogen on the basis of specialist advice.</li><li>The information that some women on systemic HRT may benefit from vaginal oestrogen therapy is based on the NICE clinical guideline. This approach is supported by expert opinion in the BMS publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Ayres, 2020</a>].</li><li>The Endocrine Society clinical practice guideline notes that low-dose vaginal oestrogen is effective for women who have not responded to vaginal moisturizers or lubricants, based on moderate-quality evidence. Various RCTs show symptom improvement within 2–3 weeks, and it advises using the lowest effective dose to minimize risk of systemic absorption.</li><li>The North American Menopause Society position statement recommends low-dose vaginal oestrogen first-line in preference to systemic oestrogen for the management of isolated urogenital symptoms, due to its effectiveness and safety, with minimal systemic absorption.</li><li>The recommendation to consider the use of oral ospemifene if vaginal oestrogen is not tolerated or is contraindicated, is based on the EMAS position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Armeni, 2016</a>]. This approach is supported by the Endocrine Society clinical practice guideline, which recommends its use based on very low-quality evidence, but notes its lack of trial safety data in women with breast cancer.</li></ul></li><li>The recommendation on management of persistent altered sexual function is based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>], the ESHRE guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">ESHRE, 2015</a>], the BMS publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Panay, 2019</a>], and expert opinion in the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Joint Formulary Committee, 2020</a>].<ul><li>NICE found limited evidence that testosterone supplementation may increase the frequency of sexual episodes for women in surgical menopause when compared with placebo. The guideline development group emphasized that testosterone should only be offered as an option for improving low sexual desire if a trial of HRT is ineffective, particularly due to the limited evidence available and the fact this is an off-label indication.</li><li>The BMS publication notes that testosterone products such as gels or creams are not licensed for use in women in the UK for low sexual desire or arousal, but there is an option of using them off-label in women in female doses, due to the lack of specific preparations for women.</li><li>The ESHRE guideline states that women with premature ovarian insufficiency (POI) should receive adequate counselling about the possibility of using testosterone supplementation so that they can make an informed choice, in the knowledge that long-term efficacy and safety are unknown.</li><li>The BNF advises testosterone should only be prescribed for this indication following expert advice.</li></ul></li><li>The information about the doses of oestrogen therapy that may be needed in younger and older women is extrapolated from the BMS publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Ayres, 2020</a>].</li><li>The recommendation to liaise with the woman's specialist or an expert in menopause if there is uncertainty about prescribing HRT is extrapolated from an ungraded best practice statement in the Endocrine Society clinical practice guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Stuenkel, 2015</a>]. It is also pragmatic, based on what CKS considers to be good clinical practice.</li></ul><h6>Not recommending use of bioidentical hormone replacement therapy</h6><ul><li>The recommendation not to use bioidentical hormone therapy is based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>], the EMAS position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Armeni, 2016</a>], the AACE/ACE position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Cobin, 2017</a>], the North American Menopause Society position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">North American Menopause Society, 2018</a>], and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hill, 2016</a>].<ul><li>The NICE guideline notes the efficacy and safety of unregulated compounded bioidentical hormones are unknown.</li><li>The EMAS position statement defines bioidentical hormones as plant-derived medications that are structurally modified to mimic endogenous human hormones such as estradiol and progesterone, and notes concerns in the literature about safety and efficacy.</li><li>The AACE/ACE position statement advises against the use of bioidentical hormone replacement, noting that there is no good evidence to support superior safety or efficacy with these products, and there is often a lack of consistency in the content of compounded products, leading to variable quantities of biologically active hormone being taken.</li><li>The North American Menopause Society position statement recommends that compounded bioidentical hormone therapy is avoided given concerns about safety, including the possibility of overdosing or underdosing, and the lack of efficacy and safety studies.</li><li>Expert opinion in a review article also notes data are limited about the safety and effectiveness of compounded bioidentical formulations and concern that these unregulated formulations may have similar adverse effects as oestrogen therapy, such as risk of endometrial hyperplasia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hill, 2016</a>].</li></ul></li></ul><h6>Arranging regular review</h6><ul><li>The recommendations on arranging review are based on the NICE clinical guidelines on suspected cancer [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2017b</a>] and on menopause [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>], the EMAS position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Armeni, 2016</a>], the AACE consensus publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Goodman, 2011</a>], Endocrine Society clinical practice guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Stuenkel, 2015</a>], the North American Menopause Society position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">North American Menopause Society, 2018</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hill, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Pinkerton, 2020</a>].<ul><li>NICE based their recommendations on when to assess the effectiveness and safety of treatments on the clinical experience and expertise of the guideline development group, due to the lack of studies meeting the inclusion criteria in the evidence review. The North American Menopause Society recommends periodic re-evaluation of risks, benefits, health status, and treatment goals over time, based on consensus and expert opinion.</li><li>The Endocrine Society clinical practice guideline recommends assessing the efficacy and tolerability of treatment(s), as does the EMAS position statement, which recommends checking efficacy, dose, type, route of administration, and need for continued treatment at annual review.</li><li>The information on treatment options if there are bothersome adverse effects or persistent symptoms is based on the EMAS position statement, the AACE consensus publication, and the Endocrine Society clinical practice guideline.</li><li>The recommendation to arrange appropriate assessment if there is a sudden change in bleeding pattern or unscheduled vaginal bleeding is based on the NICE clinical guideline on suspected cancer, the Endocrine Society clinical practice guideline, and the AACE consensus publication.</li><li>The recommendation to consider an alternative cause for symptoms if there are persistent symptoms despite adjustment of HRT is based on the EMAS position statement and the Endocrine Society clinical practice guideline.</li><li>The recommendation to review duration of treatment at least annually, depending on treatment goals and current risk assessment, is based on an ungraded best practice statement in the Endocrine Society clinical practice guideline. The North American Menopause Society position statement recommends considering periodic trials of lowering or discontinuing HRT or changing to potentially safer low-dose transdermal routes. This approach is supported by expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Pinkerton, 2020</a>].</li></ul></li></ul><h6>Advice on when and how to stop HRT</h6><ul><li>The recommendations on stopping HRT are based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>], two EMAS position statements [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Armeni, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Mishra, 2019</a>], two BMS publications [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Ayres, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Marsden, 2020</a>], the ESHRE guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">ESHRE, 2015</a>], the Endocrine Society clinical practice guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Stuenkel, 2015</a>], the North American Menopause Society position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">North American Menopause Society, 2018</a>], and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hill, 2016</a>].<ul><li>The recommendation to continue HRT for as long as benefits outweigh risks is based on a BMS publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Ayres, 2020</a>]. The information that no arbitrary limit should be placed on the duration of HRT use is extrapolated from an additional BMS publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Marsden, 2020</a>].<ul><li>The information that most women require 2–5 years of HRT for vasomotor symptoms is extrapolated from expert opinion in a review article, which advises that the decision to continue combined hormone therapy for more than 3–5 years should be made after reviewing the risks, benefits, and symptoms with the woman [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hill, 2016</a>].</li><li>The recommendation that women with premature menopause or POI should take HRT up to the average age of the natural menopause in the UK is based on the NICE clinical guideline, the EMAS position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Mishra, 2019</a>], and low-quality evidence in the Endocrine Society clinical practice guideline. In addition, the North American Menopause Society recommends this group of women should take HRT until at least the age of anticipated menopause, based on limited evidence from observational studies of the potential prevention of risks related to early oestrogen loss on cardiovascular disease, osteoporosis, mood, sexual function, urogenital symptoms, and cognitive function. Similarly, the ESHRE guideline notes that despite a lack of longitudinal outcome data, HRT with early initiation is strongly recommended in women with POI to control future risk of cardiovascular disease, to maintain bone health, and prevent osteoporosis.</li></ul></li><li>The recommendation that HRT may be gradually reduced or stopped suddenly is based on the NICE evidence review of four RCTs of low- to very low-quality, which found the trial data was inconclusive. The guideline development group used its clinical experience and expertise to conclude that choosing either approach makes no difference to the woman's symptoms in the longer term. This recommendation is supported by the Endocrine Society clinical practice guideline, which found low-quality evidence in studies that there was no difference between the two approaches of gradually reducing or suddenly stopping treatment.<ul><li>The information that gradually reducing HRT dose may limit the recurrence of symptoms in the short term is based on the NICE clinical guideline.</li><li>The information that if troublesome symptoms recur, options include restarting low-dose HRT or considering alternative non-hormonal therapies is based on the Endocrine Society clinical practice guideline. This approach is supported by the EMAS position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Armeni, 2016</a>].</li></ul></li><li>The information that vaginal oestrogen preparations may be needed long term is based on the fact urogenital symptoms often return when treatment is stopped [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>]. Treatment may therefore be continued long term if helpful and there are no contraindications. In addition, endometrial pathology is rare following 1 year of use of vaginal oestrogens [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Armeni, 2016</a>].</li></ul></li></ul><!-- end field e53e6f70-ec60-4050-89ce-cef68d127c96 --><!-- end item 513fd924-abb9-448b-83a9-4e0a613cf978 -->","subChapters":[]}]},{"id":"a83ee61f-ff86-561d-b63e-c1b412919973","slug":"non-hormonal-treatments","fullItemName":"Non-hormonal treatments","depth":3,"htmlHeader":"<!-- begin field b25885e6-5ce7-4a79-824c-4b31849f5c69 --><h3>What non-hormonal treatments can I offer?</h3><!-- end field b25885e6-5ce7-4a79-824c-4b31849f5c69 -->","summary":null,"htmlStringContent":"<!-- begin item f3d80df6-e160-4560-a306-8a5c94ce568a --><!-- begin field 6a43f405-e56d-40d9-a85a-d67d8a96bfd6 --><p><strong>If a woman chooses not to take <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/management/management-of-menopause-perimenopause-or-premature-ovarian-insufficiency/#hormone-replacement-therapy-hrt\">hormone replacement therapy</a> (HRT), or it is <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/prescribing-information/hormone-replacement-therapy-hrt/#adverse-effects\">not tolerated</a> or is <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/prescribing-information/hormone-replacement-therapy-hrt/#contraindications-cautions\">contraindicated</a>:</strong></p><ul><li><strong>Advise on lifestyle measures for menopause symptom relief.</strong> See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/management/management-of-menopause-perimenopause-or-premature-ovarian-insufficiency/#information-lifestyle-advice\">Information and lifestyle advice</a> for more information.</li><li><strong>If lifestyle measures are insufficient, advise on non-hormonal treatments and non-drug treatment options</strong> for symptom relief, including risks and benefits.</li><li><strong>For vasomotor symptoms,</strong> consider a trial of:<ul><li>Selective serotonin reuptake inhibitors (SSRIs, off-label) or serotonin and norepinephrine reuptake inhibitors (SNRIs, off-label) for 2 weeks initially.<ul><li>Options include fluoxetine (20 mg daily), citalopram (20 mg daily), paroxetine (10 mg daily), or venlafaxine modified-release (37.5 mg daily for 1 week then increased to 75 mg once daily if needed).</li></ul></li><li>Clonidine (an alpha-2 adrenergic receptor agonist).<ul><li>Initially 50 micrograms twice daily for 2 weeks, then increased to 75 micrograms twice daily, if needed.</li></ul></li><li>Gabapentin (off-label), depending on local prescribing guidelines.<ul><li>Up to 300 mg three times a day, initial dose should be lower and titrated up over 3 days.</li></ul></li><li>Cognitive behavioural therapy (CBT), depending on local service provision.</li></ul></li><li><strong>For mood disorders, </strong>consider:<ul><li>Self-help resources and a trial of CBT for low mood and/or anxiety.</li><li>Antidepressant treatment for a confirmed diagnosis of depression and/or anxiety, if indicated. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/depression/\">Depression</a> and <a class=\"topic-reference external-reference\" href=\"/topics/generalized-anxiety-disorder/\">Generalized anxiety disorder</a> for more information.</li></ul></li><li><strong>For urogenital symptoms (genitourinary syndrome of menopause),</strong> consider a trial of:<ul><li>Vaginal moisturizers, such as Replens MD<sup>®</sup>, to be used at least twice weekly.</li><li>Vaginal lubricants if there are insufficient vaginal secretions for comfortable sexual activity.</li><li>Note: these preparations may be used alone or in addition to vaginal oestrogen preparations. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/management/management-of-menopause-perimenopause-or-premature-ovarian-insufficiency/#hormone-replacement-therapy-hrt\">Hormone replacement therapy (HRT)</a> for more information.</li></ul></li><li><strong>Advise women considering complementary therapies: </strong><ul><li>There is some evidence that isoflavones and black cohosh may relieve vasomotor symptoms, but the quality, purity, constituents, and safety of these products may be unknown, and different preparations may vary.</li></ul></li><li><strong>Arrange to review the woman after 3 months, then at least annually thereafter,</strong> unless there are clinical indications for an earlier review (such as treatment ineffectiveness or adverse effects). At each review:<ul><li>Reinforce <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/management/management-of-menopause-perimenopause-or-premature-ovarian-insufficiency/#information-lifestyle-advice\">information and lifestyle advice</a>.</li><li>Assess the efficacy and tolerability of treatment(s).</li><li>If the woman is symptom free on antidepressant treatment, consider a gradual withdrawal of treatment after 1–2 years. Advise that symptoms may recur once treatment is stopped.</li><li>Advise that the use of vaginal moisturizers and lubricants may be continued indefinitely.</li></ul></li><li><strong>Offer to refer the woman to a healthcare professional with expertise in menopause, </strong>if treatments do not improve menopausal symptoms. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/management/management-of-menopause-perimenopause-or-premature-ovarian-insufficiency/#referral\">Referral</a> for more information.</li></ul><!-- end field 6a43f405-e56d-40d9-a85a-d67d8a96bfd6 --><!-- end item f3d80df6-e160-4560-a306-8a5c94ce568a -->","subChapters":[{"id":"1f498cf2-a116-58c1-ba66-72875e777b39","slug":"basis-for-recommendation-e78","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field ad0967ee-c591-4138-afb1-31b61169284b --><h4>Basis for recommendation</h4><!-- end field ad0967ee-c591-4138-afb1-31b61169284b -->","summary":null,"htmlStringContent":"<!-- begin item e78aa6fa-c80d-42c2-87a9-2aa3d7aa9e5f --><!-- begin field 04406617-7dd0-4082-9e4b-a65de640e70a --><p>The recommendations on non-hormonal and non-drug treatments are largely based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Menopause</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>]; the European Menopause and Andropause Society (EMAS) position statements <em>Non-hormonal management of menopausal vasomotor symptoms</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Mintziori, 2015</a>] and <em>Maintaining postreproductive health: a care pathway from the European Menopause and Andropause Society (EMAS)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Armeni, 2016</a>]; the British Menopause Society (BMS) publication <em>Consensus on the management of estrogen deficiency symptoms, arthralgia, and menopause diagnosis in women treated for early breast cancer</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Marsden, 2019</a>]; the Endocrine Society clinical practice guideline <em>Treatment of symptoms of the menopause</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Stuenkel, 2015</a>]; the American Association of Clinical Endocrinologists (AACE) consensus publication <em>Medical guidelines for clinical practice for the diagnosis and treatment of menopause</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Goodman, 2011</a>]; the AACE and American College of Endocrinology (ACE) <em>Position statement on menopause - 2017 update</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Cobin, 2017</a>]; the North American Menopause Society position statement <em>Nonhormonal management of menopause-associated vasomotor symptoms</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">North American Menopause Society, 2015</a>]; a Cochrane systematic review <em>Chinese herbal medicine for menopausal symptoms</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Zhu, 2016</a>]; a systematic review on psychological interventions for menopausal symptoms [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">van Driel, 2019</a>]; the UK Medicines Information (UKMi) publication on the use of antidepressant medication for hot flushes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">UKMi, 2019</a>]; and expert opinion in review articles on hormonal treatments [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hill, 2016</a>] and on non-hormonal treatments [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hickey, 2017</a>].</p><h6>Non-hormonal treatments for vasomotor symptoms</h6><ul><li>The recommendations on non-hormonal treatments for vasomotor symptoms are based on limited evidence in the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>], the EMAS position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Mintziori, 2015</a>], the Endocrine Society clinical practice guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Stuenkel, 2015</a>], the AACE/ACE position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Cobin, 2017</a>], the North American Menopause Society position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">North American Menopause Society, 2015</a>], a systematic review on psychological therapies [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">van Driel, 2019</a>], the UKMi publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">UKMi, 2019</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hill, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hickey, 2017</a>] and in the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Joint Formulary Committee, 2020</a>].<ul><li>The NICE clinical guideline states that selective serotonin reuptake inhibitors (SSRIs) or serotonin and norepinephrine reuptake inhibitors (SNRIs) should not be routinely offered as first-line treatment for women with vasomotor symptoms alone. It reviewed evidence from 51 studies to assess the relative clinical effectiveness of the most common treatments used to relieve short-term menopausal symptoms. The guideline development group acknowledged that some women would not wish to take hormonal therapy or it may be contraindicated. Alternative treatments, including SSRIs and SNRIs, testosterone, herbal remedies, vaginal moisturisers and lubricants, and non-pharmacological therapies, were also considered.<ul><li>It found SSRIs and SNRIs were ineffective in relieving vasomotor symptoms, and also had significantly higher rates of discontinuation than other treatments.</li><li>It states that clonidine should not be routinely offered as first-line treatment for vasomotor symptoms alone.</li></ul></li><li>The recommendation to consider an initial 2-week trial of SSRI or SNRI treatment is based on the UKMi publication, which states that a short-term trial possibly up to 4 weeks should be adequate to assess the effect of SSRI or SNRI treatment on hot flushes. This approach is supported by the North American Menopause Society position statement that notes that for SSRIs, SNRIs, and gabapentinoids the onset of action is rapid, usually within 2 weeks.</li><li>The EMAS position statement notes that SSRIs such as escitalopram, citalopram, sertraline, and paroxetine are effective in decreasing the severity and frequency of vasomotor symptoms, and SNRIs and gabapentin are alternatives to HRT for the management of vasomotor symptoms.<ul><li>It highlighted a high level of heterogeneity of studies and high drop-out rates in gabapentin treatment groups due to adverse effects, which limited the quality of evidence of benefit.</li><li>It also stated that clonidine can be considered as a treatment option.</li><li>It found limited evidence supporting the use of cognitive behavioural therapy (CBT) for management of vasomotor symptoms.</li></ul></li><li>The AACE/ACE position statement recommends that in women at significant risk from using hormone replacement therapy (HRT), the use of SSRIs and other non-hormonal agents may offer symptom relief.<ul><li>It found evidence of moderate efficacy for the use of SSRIs for treatment of hot flushes.</li><li>It found evidence from placebo-controlled trials that gabapentin reduces hot flushes compared with placebo.</li></ul></li><li>The Endocrine Society clinical practice guideline recommends the use of SSRIs, SNRIs, gabapentin, or pregabalin if a woman has moderate-to-severe vasomotor symptoms, and HRT is not wanted or contraindicated, based on moderate-quality evidence.<ul><li>Clinical trials of citalopram, escitalopram, and venlafaxine showed a reduction in frequency of hot flushes from 25% to 69%, and trials of sertraline and fluoxetine showed a non-statistically significant trend towards reduction in hot flushes, but inconsistent results. The guideline notes that a significant placebo effect is known in the literature, particularly in women with high anxiety and stress scores.</li><li>Four randomized controlled trials (RCTs) of gabapentin showed moderate efficacy in relieving hot flushes. One 6-week RCT of pregabalin found it decreased mean hot flush scores by 65% and 71% compared with a score of 50% in women using placebo. </li><li>It also states a trial of clonidine may be considered as a second-line treatment option for moderate-to-severe vasomotor symptoms if an SSRI or SNRI is ineffective or not tolerated, based on low-quality evidence. It cites evidence for clonidine from several RCTs that it reduced hot flushes with less efficacy than other agents, and with more potential adverse effects. </li></ul></li><li>The North American Menopause Society position statement highlights that:<ul><li>SSRIs, SNRIs, gabapentinoids, and clonidine show evidence of efficacy and are recommended.</li><li>CBT and, to a lesser extent, clinical hypnosis are effective treatments for vasomotor symptoms in women with breast cancer and other menopausal women, based on good-quality evidence from RCTs.</li><li>No clear recommendations can be given for efficacy of one non-hormonal drug treatment over another because there are few head-to-head comparison efficacy trials, and trials have a varying number and severity of hot flushes as outcome measures.</li></ul></li><li>Expert opinion in a review article recommends use of low-dose SSRIs, SNRIs, or gabapentin for management of vasomotor symptoms. It notes that clonidine has multiple potential adverse effects, such as hypotension, dizziness, and rebound hypertension, that may limit its use [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hill, 2016</a>].</li><li>The suggested doses of non-hormonal treatments and the information that some treatments are off-label are based on expert opinion in the BNF [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Joint Formulary Committee, 2020</a>].</li><li>A systematic review of 12 RCTs concluded that mindfulness, cognitive behavioural and behaviour-based therapy may be useful for the treatment of natural and treatment-induced menopausal symptoms, particularly hot flushes in the short and medium term, as they caused a small-to-moderate reduction in symptoms compared with no treatment or control [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">van Driel, 2019</a>]. <ul><li>There were insufficient studies to perform a meta-analysis on the effect of psychological interventions on sexual functioning, and the authors noted a high level of heterogeneity in the meta-analysis due to differences in the study populations and differences in intervention type and duration.</li></ul></li><li>Furthermore, expert opinion in a review article cites studies that CBT effectively reduced the impact of vasomotor symptoms in women with and without a history of breast cancer [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hickey, 2017</a>].</li></ul></li></ul><h6>Non-hormonal treatments for mood disorders</h6><ul><li>The recommendations for non-hormonal treatments for mood disorders are based on limited evidence in the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>], which found that low mood and anxiety as a result of the menopause can be alleviated by psychological therapies, such as CBT, but not by the other non-pharmacological treatments reviewed, such as herbal treatments.<ul><li>NICE found that CBT, isoflavones, and red clover significantly reduced anxiety compared with placebo or usual care, however, due to a lack of consistency between the constituents of herbal preparations and isoflavones, and concerns regarding the safety of these products, the guideline development group decided that CBT was the preferred option, and recommends that CBT can be considered to reduce low mood or anxiety that arise as a result of the menopause.</li><li>It noted limited evidence that SSRIs may be effective in symptomatic menopausal women with anxiety, but there was no clear evidence for SSRIs and SNRIs to improve low mood in menopausal women who have not been diagnosed with depression. Women treated with SSRIs also had higher rates of discontinuation compared with other treatments. The guideline development group concluded that SSRIs and SNRIs should not be used first-line for low mood for menopausal women who are not diagnosed with depression.</li></ul></li></ul><h6>Non-hormonal treatments for urogenital symptoms</h6><ul><li>The recommendations for the use of vaginal moisturizers and lubricants for urogenital symptoms are based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>], the EMAS position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Armeni, 2016</a>], the Endocrine Society clinical practice guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Stuenkel, 2015</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hill, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hickey, 2017</a>].<ul><li>NICE did not review any studies on the use of vaginal moisturizers and lubricants, however, the guideline development group considered that these are safe options for the relief of vaginal symptoms in menopausal women, based on their clinical experience and expertise.</li><li>The information that vaginal moisturizers should be used at least twice weekly is based on low-quality evidence in the Endocrine Society clinical practice guideline.</li><li>The information that moisturizers and lubricants can be used alone or in addition to vaginal oestrogen is based on the NICE clinical guideline.</li></ul></li></ul><h6>Advice on complementary therapies</h6><ul><li>The information on complementary therapies is based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>], the EMAS position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Mintziori, 2015</a>], the AACE consensus publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Goodman, 2011</a>], the North American Menopause Society position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">North American Menopause Society, 2015</a>], the Endocrine Society clinical practice guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Stuenkel, 2015</a>], a Cochrane systematic review [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Zhu, 2016</a>], and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hill, 2016</a>].<ul><li>NICE found some evidence that isoflavones and black cohosh may relieve vasomotor symptoms compared with placebo, but advised the results should be interpreted with caution as the quality, purity, and constituents of preparations may be unknown, multiple preparations are available with uncertain safety profiles, and different preparations may have potential drug interactions.</li><li>The Endocrine Society clinical practice guideline found a lack of consistent evidence of benefit for botanicals, black cohosh, omega-3-fatty acids, red clover, and vitamin E, based on low-quality evidence. The guideline notes that clinical trials show inconsistent efficacy over placebo, but some women may experience a benefit.</li><li>The North American Menopause Society position statement found negative, insufficient, or inconclusive data suggesting that over-the-counter supplements and herbal therapies (including black cohosh, crinum, dioscorea, dong quai, evening primrose, flaxseed, ginseng, hops, maca, omega-3s, pine bark, pollen extract, puerperia, Siberian ginseng, and vitamin supplementation) should not be recommended as proven therapies for managing vasomotor symptoms.</li><li>The AACE consensus publication notes that phytoestrogens, including soy-derived isoflavonoids, result in inconsistent relief of symptoms. It recommends that as these compounds may have oestrogenic effects, women with a personal or strong family history of hormone-dependent cancers, thromboembolic events, or cardiovascular events should not use soy-based therapies.</li><li>The EMAS position statement notes conflicting evidence on the efficacy and safety of herbal supplements.</li><li>A Cochrane systematic review of 22 RCTs (n = 2902 women) studying the effectiveness and safety of Chinese herbal medicine preparations for vasomotor symptoms found insufficient evidence that these preparations were any more or less effective than placebo or HRT, and the effects on safety were inconclusive.</li><li>Expert opinion in a review article notes there is no high-quality, consistent evidence that alternative therapies such as black cohosh, botanical products, omega-3 fatty acid supplements, and dietary Chinese herbs benefit women more than placebo, based on limited evidence [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hill, 2016</a>].</li></ul></li></ul><h6>Arranging regular review</h6><ul><li>The recommendations on arranging review are based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>], the North American Menopause Society position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">North American Menopause Society, 2015</a>], the UKMi publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">UKMi, 2019</a>], and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hickey, 2017</a>].<ul><li>NICE based their recommendations on when to assess the effectiveness and safety of treatments on the clinical experience and expertise of the guideline development group, due to the lack of studies meeting the inclusion criteria in the evidence review.</li><li>The North American Menopause Society position statement states that therapy should be carefully re-evaluated on a regular basis such as every 6–12 months, as data on long-term use are limited. Similarly, expert opinion in a review article states that if treatments are helping, the woman should be reassessed every 6–12 months [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hickey, 2017</a>].</li><li>The recommendation to consider a gradual withdrawal of antidepressant treatment if clinically indicated, is extrapolated from the North American Menopause Society position statement, which notes limited evidence from clinical trials suggesting that non-hormonal therapy should be gradually tapered over 1 to 2 weeks to avoid drug withdrawal symptoms. It is also pragmatic, based on what CKS considers to be good clinical practice. The UKMi publication notes there is no consensus in the literature on the optimal duration of treatment with antidepressants for women with vasomotor symptoms.</li><li>The information that vaginal moisturizers and lubricants may be used indefinitely is pragmatic, based on what CKS considers to be safe clinical practice.</li></ul></li></ul><!-- end field 04406617-7dd0-4082-9e4b-a65de640e70a --><!-- end item e78aa6fa-c80d-42c2-87a9-2aa3d7aa9e5f -->","subChapters":[]}]},{"id":"5b93419c-266a-5b9d-b23e-5358f351c399","slug":"managing-co-morbidities","fullItemName":"Managing co-morbidities","depth":3,"htmlHeader":"<!-- begin field ae768ec4-f44a-40cb-b2ac-060f8ba5a081 --><h3>How should I manage women with comorbidities?</h3><!-- end field ae768ec4-f44a-40cb-b2ac-060f8ba5a081 -->","summary":null,"htmlStringContent":"<!-- begin item dbeeb1a9-4834-471b-961c-8ebcff203bee --><!-- begin field 9330159c-6579-40c2-831a-ff0cf3ffafcd --><p><strong>For women with <strong><a class=\"topic-reference internal-reference\" href=\"/topics/menopause/management/management-of-menopause-perimenopause-or-premature-ovarian-insufficiency/#managing-co-morbidities\">co-morbidities</a></strong>, offer <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/management/management-of-menopause-perimenopause-or-premature-ovarian-insufficiency/#hormone-replacement-therapy-hrt\">hormonal</a>, <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/management/management-of-menopause-perimenopause-or-premature-ovarian-insufficiency/#non-hormonal-treatments\">non-hormonal, or non-drug</a> treatment options depending on the <strong><a class=\"topic-reference internal-reference\" href=\"/topics/menopause/management/management-of-menopause-perimenopause-or-premature-ovarian-insufficiency/#risks-of-hrt\">risks</a></strong>, <strong><a class=\"topic-reference internal-reference\" href=\"/topics/menopause/management/management-of-menopause-perimenopause-or-premature-ovarian-insufficiency/#benefits-of-hrt\">benefits</a></strong>, <strong><a class=\"topic-reference internal-reference\" href=\"/topics/menopause/prescribing-information/hormone-replacement-therapy-hrt/#adverse-effects\">adverse effects</a></strong>, and <strong><a class=\"topic-reference internal-reference\" href=\"/topics/menopause/prescribing-information/hormone-replacement-therapy-hrt/#contraindications-cautions\">contraindications</a></strong>. If there is any uncertainty about appropriate management, seek specialist advice from a healthcare professional with expertise in menopause or refer to the relevant specialist team.</strong></p><ul><li><strong>Women with, or at high risk of, breast cancer:</strong><ul><li>Stop systemic hormone replacement therapy (HRT) in women who are diagnosed with breast cancer. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/breast-cancer-recognition-referral/\">Breast cancer - recognition and referral</a> for more information.</li><li>Do not offer HRT routinely to women with menopausal symptoms and a history of breast cancer.<ul><li>Seek specialist advice if a woman wishes to consider the use of hormonal therapy, such as treatment with low-dose vaginal oestrogen.</li></ul></li><li>Advise on lifestyle measures, non-hormonal, and non-drug treatment options for symptom relief.<ul><li>Advise that women taking tamoxifen should not use fluoxetine or paroxetine, as they may inhibit the effect of tamoxifen.</li></ul></li><li>Do not recommend the use of isoflavones, red clover, black cohosh, vitamin E, or magnetic devices to treat menopausal symptoms in women with breast cancer.<ul><li>Advise that the herbal preparation St John's wort may interact with other drugs such as tamoxifen, anticoagulants, and anticonvulsants. In addition, there is uncertainty about the appropriate dose, and possible variation of potency of over-the-counter preparations.</li></ul></li></ul></li><li><strong>Women with increased risk of venous thromboembolism (VTE):</strong><ul><li>Consider the use of transdermal rather than oral HRT for women at increased risk of VTE, including women with a BMI over 30 kg/m<sup>2</sup>.</li><li>Consider referring women at high risk of VTE (for example, with a strong family history of VTE or a hereditary thrombophilia) to a haematologist for assessment before considering the use of HRT.</li></ul></li><li><strong>Women with increased risk of cardiovascular disease (CVD):</strong><ul><li>Manage any cardiovascular risk factors before considering the use of HRT. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a>, <a class=\"topic-reference external-reference\" href=\"/topics/lipid-modification-cvd-prevention/\">Lipid modification - CVD prevention</a>, <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-not-diabetic/\">Hypertension - not diabetic</a>, <a class=\"topic-reference external-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/\">Non-alcoholic fatty liver disease (NAFLD)</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a> for more information.<ul><li>Be aware that the presence of cardiovascular risk factors is not a contraindication to taking HRT as long as they are optimally managed.</li></ul></li><li>Consider the use of transdermal rather than oral HRT for women at increased risk of CVD.</li></ul></li><li><strong>Women with type 2 diabetes:</strong><ul><li>Consider the use of HRT after taking any other co-morbidities into account.<ul><li>Advise that HRT is not associated with an adverse effect on blood glucose control.</li></ul></li><li>See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a> for more information.</li></ul></li><li><strong>Women with hypothyroidism:</strong><ul><li>Advise that thyroid-stimulating hormone (TSH) levels should be monitored regularly (for example, 6–12 weeks after starting oral HRT), to ensure that levels remain in the acceptable range, as the dose of levothyroxine (LT4) medication may need to be increased. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypothyroidism/\">Hypothyroidism</a> for more information.</li></ul></li></ul><!-- end field 9330159c-6579-40c2-831a-ff0cf3ffafcd --><!-- end item dbeeb1a9-4834-471b-961c-8ebcff203bee -->","subChapters":[{"id":"6ae7366f-64ba-5247-a2f3-56159887c767","slug":"basis-for-recommendation-153","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 84f0b5df-777a-4f5b-aa72-c2567af88212 --><h4>Basis for recommendation</h4><!-- end field 84f0b5df-777a-4f5b-aa72-c2567af88212 -->","summary":null,"htmlStringContent":"<!-- begin item 153913b7-2e95-409d-bda3-76761c4ff001 --><!-- begin field c406c614-c043-4e81-a75d-4fcb23fef138 --><p>The recommendations on managing co-morbidities are based on the National Institute for Health and Care Excellence (NICE) clinical guidelines <em>Early and locally advanced breast cancer: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2018</a>] and <em>Menopause</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>]; the European Menopause and Andropause Society clinical guideline <em>Menopause symptom management in women with dyslipidemias</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Anagnostis, 2020</a>]; the British Menopause Society (BMS) publications <em>Consensus on the management of estrogen deficiency symptoms, arthralgia, and menopause diagnosis in women treated for early breast cancer</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Marsden, 2019</a>] and <em>The risks and benefits of HRT before and after a breast cancer diagnosis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Marsden, 2020</a>]; the Endocrine Society clinical practice guideline <em>Treatment of symptoms of the menopause</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Stuenkel, 2015</a>]; the American Association of Clinical Endocrinologists (AACE) consensus publication <em>Medical guidelines for clinical practice for the diagnosis and treatment of menopause</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Goodman, 2011</a>]; the AACE and American College of Endocrinology (ACE) <em>Position statement on menopause - 2017 update</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Cobin, 2017</a>]; the North American Menopause Society position statement on hormonal therapy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">North American Menopause Society, 2018</a>]; and expert opinion in review articles on hormonal treatments [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hill, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Pinkerton, 2020</a>] and on non-hormonal treatments [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hickey, 2017</a>].</p><h6>Breast cancer</h6><ul><li>The recommendation to stop systemic hormone replacement therapy (HRT) in women who are diagnosed with breast cancer is based on the NICE clinical guideline on breast cancer [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2018</a>].</li><li>The recommendation not to offer HRT routinely to women with menopausal symptoms and a history of breast cancer is based on the NICE clinical guideline on breast cancer [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2018</a>].<ul><li>The recommendation to seek specialist advice if the woman wishes to consider the use of low-dose vaginal oestrogen is based on the Endocrine Society clinical practice guideline, which recommends that for women with a history of breast or endometrial cancer, decisions about the use of low-dose vaginal oestrogen for persistent urogenital symptoms should be made with the woman's oncologist or specialist [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Stuenkel, 2015</a>]. This approach is in line with consensus and expert opinion in the North American Menopause Society position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">North American Menopause Society, 2018</a>] and is supported by the BMS publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Marsden, 2019</a>]. The NICE clinical guideline on breast cancer notes that in exceptional circumstances, HRT may be offered to women with severe menopausal symptoms unresponsive to other treatments, if the associated risks have been discussed with the woman's specialist [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2018</a>].</li></ul></li><li>The recommendation to consider the use of lifestyle measures, non-hormonal, and non-drug treatment options for symptom relief, such as some selective serotonin reuptake inhibitors (SSRIs) is based on the NICE clinical guideline on breast cancer [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2018</a>], the Endocrine Society clinical practice guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Stuenkel, 2015</a>], consensus, and expert opinion in the North American Menopause Society position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">North American Menopause Society, 2018</a>], and is supported by the BMS publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Marsden, 2019</a>].<ul><li>The information that women taking tamoxifen should not use fluoxetine or paroxetine is based on the NICE clinical guideline on menopause [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>], the AACE/ACE position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Cobin, 2017</a>], and expert opinion in the BMS publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Marsden, 2019</a>] and in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hickey, 2017</a>].</li></ul></li><li>The recommendation not to use isoflavones, red clover, black cohosh, vitamin E, or magnetic devices to treat menopausal symptoms in women with breast cancer is based on the NICE clinical guideline on breast cancer [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2018</a>].<ul><li>The information on the potential safety issues with over-the-counter use of St John's wort is based on the NICE clinical guideline on menopause [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>] and is supported by the BMS publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Marsden, 2019</a>].</li></ul></li></ul><h6>Venous thromboembolism (VTE)</h6><ul><li>The recommendation to consider the use of transdermal rather than oral HRT for women at increased risk of VTE is based on the NICE clinical guideline on menopause, as the risk of VTE is increased by oral HRT compared with baseline population risk [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>]. This approach is supported by the Endocrine Society clinical practice guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Stuenkel, 2015</a>], the AACE consensus publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Goodman, 2011</a>], and the AACE/ACE position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Cobin, 2017</a>]. Expert opinion in a review article notes that although there are no randomized trials, observational studies have shown that transdermal oestrogen, which avoids the first-pass liver effect, may have a lower risk of VTE compared with oral oestrogen [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hill, 2016</a>].</li><li>The recommendation to consider referring women at high risk of VTE to a haematologist for assessment before considering use of HRT is based on the NICE clinical guideline on menopause [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>].</li></ul><h6>Cardiovascular disease (CVD)</h6><ul><li>The recommendation to manage any cardiovascular risk factors is based on the NICE clinical guideline on menopause, which notes that HRT does not increase CVD risk when started in women aged under 60 years, and HRT does not affect the risk of dying from CVD [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>]. It is also pragmatic, based on what CKS considers to be good clinical practice.<ul><li>The information that cardiovascular risk factors are not a contraindication to use of HRT provided they are optimally managed is based on the NICE clinical guideline on menopause [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>].</li></ul></li><li>The recommendation to consider the use of transdermal rather than oral HRT for women at increased risk of CVD is based on the EMAS clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Anagnostis, 2020</a>], the Endocrine Society clinical practice guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Stuenkel, 2015</a>], the AACE consensus publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Goodman, 2011</a>], the AACE/ACE position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Cobin, 2017</a>], and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Pinkerton, 2020</a>].</li></ul><h6>Type 2 diabetes mellitus</h6><ul><li>The recommendation to consider the use of HRT in women with type 2 diabetes mellitus after taking co-morbidities into account is based on the NICE clinical guideline on menopause [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>]. This approach is supported by the AACE/ACE position statement, which recommends that decisions about the use of HRT in these women should be individualized, taking into account the woman's age, metabolic profile, and cardiovascular risk factors [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Cobin, 2017</a>].<br><ul><li>The information that HRT is not associated with an adverse effect on blood glucose control is based on the NICE clinical guideline on menopause [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>].</li></ul></li></ul><h6>Hypothyroidism</h6><ul><li>The recommendation to monitor serum thyroid-stimulating hormone (TSH) level in a woman with hypothyroidism after starting HRT is based on the Endocrine Society clinical practice guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Stuenkel, 2015</a>].</li></ul><!-- end field c406c614-c043-4e81-a75d-4fcb23fef138 --><!-- end item 153913b7-2e95-409d-bda3-76761c4ff001 -->","subChapters":[]}]},{"id":"6385b7b6-7891-5a33-a642-e634fa508497","slug":"referral","fullItemName":"Referral","depth":3,"htmlHeader":"<!-- begin field 6da8572d-3b7d-4b84-ba52-ac7200e01277 --><h3>When should I refer a woman with menopausal symptoms?</h3><!-- end field 6da8572d-3b7d-4b84-ba52-ac7200e01277 -->","summary":null,"htmlStringContent":"<!-- begin item 9141d58c-2448-49d5-a4bf-b5c4a504e866 --><!-- begin field 0963c73c-0579-49a9-ba14-ac7200e01277 --><p><strong>If a woman has menopausal symptoms, consider arranging referral to a healthcare professional with expertise in menopause if:</strong></p><ul><li>The woman has ongoing symptoms and <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/management/management-of-menopause-perimenopause-or-premature-ovarian-insufficiency/#information-lifestyle-advice\">lifestyle measures</a>, <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/management/management-of-menopause-perimenopause-or-premature-ovarian-insufficiency/#hormone-replacement-therapy-hrt\">hormonal</a>, <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/management/management-of-menopause-perimenopause-or-premature-ovarian-insufficiency/#non-hormonal-treatments\">non-hormonal, or non-drug</a> treatments are ineffective.</li><li>The woman has persistent, troublesome <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/prescribing-information/hormone-replacement-therapy-hrt/#adverse-effects\">adverse effects</a> from treatment.</li><li>There is uncertainty about the most suitable treatment option, for example if the woman has <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/management/management-of-menopause-perimenopause-or-premature-ovarian-insufficiency/#managing-co-morbidities\">co-morbidities</a> and/or <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/prescribing-information/hormone-replacement-therapy-hrt/#contraindications-cautions\">contraindications</a> to treatment.</li><li>The woman has persistent altered sexual function and <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/management/management-of-menopause-perimenopause-or-premature-ovarian-insufficiency/#hormone-replacement-therapy-hrt\">hormonal</a> and/or <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/management/management-of-menopause-perimenopause-or-premature-ovarian-insufficiency/#non-hormonal-treatments\">non-hormonal, or non-drug</a> treatments are ineffective:<ul><li>Seek specialist advice regarding the use of testosterone supplementation (off-label use).</li><li>Consider referral for psychosexual counselling, depending on the woman's wishes.</li></ul></li><li>There is uncertainty about diagnosing <a class=\"topic-reference internal-reference\" href=\"/topics/menopause/diagnosis/diagnosis-of-premature-ovarian-insufficiency/\">premature ovarian insufficiency</a>, or specialist advice is needed to manage the condition.</li><li>There is a sudden change in menstrual pattern, intermenstrual bleeding, postcoital bleeding, or postmenopausal bleeding — assess appropriately and arrange an urgent 2-week referral if a gynaecological cancer is suspected. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/gynaecological-cancers-recognition-referral/\">Gynaecological cancers - recognition and referral</a> for more information.</li></ul><!-- end field 0963c73c-0579-49a9-ba14-ac7200e01277 --><!-- end item 9141d58c-2448-49d5-a4bf-b5c4a504e866 -->","subChapters":[{"id":"65c296a3-3fb7-504f-ad87-d34c00e28d9a","slug":"basis-for-recommendation-8f6","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 9e0ec3f5-d0d3-4010-b599-ac7200e01277 --><h4>Basis for recommendation</h4><!-- end field 9e0ec3f5-d0d3-4010-b599-ac7200e01277 -->","summary":null,"htmlStringContent":"<!-- begin item 8f68ee38-833b-4eff-86da-3d23efb92f88 --><!-- begin field c3aed141-14ee-4fce-96f2-ac7200e01277 --><p>The recommendations on referral are based on the National Institute for Health and Care Excellence (NICE) clinical guidelines <em>Menopause</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>] and <em>Suspected cancer: recognition and referral</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2017b</a>]; the European Menopause and Andropause Society (EMAS) position statement <em>Maintaining postreproductive health: a care pathway from the European Menopause and Andropause Society (EMAS)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Armeni, 2016</a>]; the British Menopause Society (BMS) publications <em>Consensus on the management of estrogen deficiency symptoms, arthralgia, and menopause diagnosis in women treated for early breast cancer</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Marsden, 2019</a>] and <em>HRT-guide</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Ayres, 2020</a>]; the European Society of Human Reproduction and Embryology (ESHRE) guideline <em>Management of women with premature ovarian insufficiency</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">ESHRE, 2015</a>]; the Endocrine Society clinical practice guideline <em>Treatment of symptoms of the menopause</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Stuenkel, 2015</a>]; the AACE consensus publication <em>Medical guidelines for clinical practice for the diagnosis and treatment of menopause</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Goodman, 2011</a>]; and expert opinion in a review article on non-hormonal treatments [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hickey, 2017</a>].</p><ul><li>The recommendation if there are ongoing symptoms is based on the expertise and clinical experience of the NICE guideline development group [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>] and is supported by the BMS publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Ayres, 2020</a>] and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Hickey, 2017</a>].</li><li>The recommendation if there are persistent, troublesome adverse effects is based on the expertise and clinical experience of the NICE guideline development group [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>] and is supported by the BMS publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Ayres, 2020</a>].</li><li>The recommendation on uncertainty about the most suitable treatment option due to co-morbidities and/or contraindications to treatment is based on the expertise and clinical experience of the NICE guideline development group [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>] and is supported by the BMS publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Ayres, 2020</a>].</li><li>The recommendation to seek specialist advice about possible testosterone supplementation for a woman with persistent altered sexual function is based on the NICE clinical guideline on menopause [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>]. It is also extrapolated from the EMAS position statement, which notes that women with premature menopause and reduced libido may be testosterone-deficient and may benefit from testosterone supplementation following specialist advice [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Armeni, 2016</a>]. The information that this treatment is off-label is based on expert opinion in the British National Formulary (BNF) that also recommends seeking specialist advice before prescribing [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Joint Formulary Committee, 2020</a>].</li><li>The recommendation to consider referral for psychosexual counselling for a woman with persistent altered sexual function is extrapolated from the BMS publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Marsden, 2019</a>].</li><li>The recommendation on the diagnosis and/or management of premature ovarian insufficiency (POI) is based on the NICE clinical guideline on menopause, which recommends referral if a woman is likely to go through menopause as a result of medical or surgical treatment (including women with cancer, at high risk of hormone-sensitive cancer, or having gynaecological surgery). It also suggests that anti-Müllerian hormone (AMH) testing may be appropriate to confirm a diagnosis of POI after seeking specialist advice [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2019</a>]. In addition, the ESHRE guideline notes that women with suspected non-iatrogenic POI may need specialist genetic/chromosomal and autoantibody testing to assess for an underlying cause [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">ESHRE, 2015</a>]. The EMAS position statement notes that some women with premature surgical menopause may be symptomatic from testosterone deficiency and may benefit from testosterone supplementation following specialist advice [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Armeni, 2016</a>].</li><li>The recommendation to assess appropriately if there is suspected gynaecological cancer is based on the NICE clinical guideline on suspected cancer [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">NICE, 2017b</a>]. This approach is supported by the Endocrine Society clinical practice guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Stuenkel, 2015</a>] and the AACE consensus publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menopause/references/\">Goodman, 2011</a>].</li></ul><!-- end field c3aed141-14ee-4fce-96f2-ac7200e01277 --><!-- end item 8f68ee38-833b-4eff-86da-3d23efb92f88 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}